166 related articles for article (PubMed ID: 17473204)
21. Hormone receptor status does not affect the clinical benefit of trastuzumab therapy for patients with metastatic breast cancer.
Brufsky A; Lembersky B; Schiffman K; Lieberman G; Paton VE
Clin Breast Cancer; 2005 Aug; 6(3):247-52. PubMed ID: 16137436
[TBL] [Abstract][Full Text] [Related]
22. [Herceptin therapy in breast cancer: new indication?].
Lebeau A
Verh Dtsch Ges Pathol; 2006; 90():99-106. PubMed ID: 17867585
[TBL] [Abstract][Full Text] [Related]
23. HER-2/neu protein-receptor-positive breast carcinoma: an immunologic perspective.
Brown RE; Bernath AM; Lewis GO
Ann Clin Lab Sci; 2000 Jul; 30(3):249-58. PubMed ID: 10945564
[TBL] [Abstract][Full Text] [Related]
24. Increased regulatory T-cell frequencies in patients with advanced melanoma correlate with a generally impaired T-cell responsiveness and are restored after dendritic cell-based vaccination.
Correll A; Tuettenberg A; Becker C; Jonuleit H
Exp Dermatol; 2010 Aug; 19(8):e213-21. PubMed ID: 20500773
[TBL] [Abstract][Full Text] [Related]
25. Absolute of CD4(+)CD25(+)FOXP3(+) regulatory T-cell count rather than its ratio in peripheral blood is related to long-term survival of renal allografts.
Liu L; Deng S; Teng L; Fu Q; Wang C; He X
Transplant Proc; 2012 Jan; 44(1):284-6. PubMed ID: 22310634
[TBL] [Abstract][Full Text] [Related]
26. Trastuzumab administration can effectively target chemotherapy-resistant cytokeratin-19 messenger RNA-positive tumor cells in the peripheral blood and bone marrow of patients with breast cancer.
Bozionellou V; Mavroudis D; Perraki M; Papadopoulos S; Apostolaki S; Stathopoulos E; Stathopoulou A; Lianidou E; Georgoulias V
Clin Cancer Res; 2004 Dec; 10(24):8185-94. PubMed ID: 15623593
[TBL] [Abstract][Full Text] [Related]
27. Pathologic complete response to trastuzumab-based neoadjuvant therapy is related to the level of HER-2 amplification.
Arnould L; Arveux P; Couturier J; Gelly-Marty M; Loustalot C; Ettore F; Sagan C; Antoine M; Penault-Llorca F; Vasseur B; Fumoleau P; Coudert BP
Clin Cancer Res; 2007 Nov; 13(21):6404-9. PubMed ID: 17975153
[TBL] [Abstract][Full Text] [Related]
28. Targeting Her-2/neu in breast cancer: as easy as this!
Azim H; Azim HA
Oncology; 2008; 74(3-4):150-7. PubMed ID: 18708732
[TBL] [Abstract][Full Text] [Related]
29. Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy.
Taylor C; Hershman D; Shah N; Suciu-Foca N; Petrylak DP; Taub R; Vahdat L; Cheng B; Pegram M; Knutson KL; Clynes R
Clin Cancer Res; 2007 Sep; 13(17):5133-43. PubMed ID: 17785568
[TBL] [Abstract][Full Text] [Related]
30. Commentary: can circulating HER-2 extracellular domain predict response to trastuzumab in HER-2-negative breast cancer?
Esteva FJ
Oncologist; 2008 Apr; 13(4):370-2. PubMed ID: 18448550
[No Abstract] [Full Text] [Related]
31. Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC).
Giuliani R; Durbecq V; Di Leo A; Paesmans M; Larsimont D; Leroy JY; Borms M; Vindevoghel A; Jerusalem G; D'Hondt V; Dirix L; Canon JL; Richard V; Cocquyt V; Majois F; Reginster M; Demol J; Kains JP; Delree P; Keppens C; Sotiriou C; Piccart MJ; Cardoso F
Eur J Cancer; 2007 Mar; 43(4):725-35. PubMed ID: 17251007
[TBL] [Abstract][Full Text] [Related]
32. Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer.
Goldenberg MM
Clin Ther; 1999 Feb; 21(2):309-18. PubMed ID: 10211534
[TBL] [Abstract][Full Text] [Related]
33. Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study.
Semiglazov V; Eiermann W; Zambetti M; Manikhas A; Bozhok A; Lluch A; Tjulandin S; Sabadell MD; Caballero A; Valagussa P; Baselga J; Gianni L
Eur J Surg Oncol; 2011 Oct; 37(10):856-63. PubMed ID: 21843921
[TBL] [Abstract][Full Text] [Related]
34. CD4CD25+ regulatory T cells in patients with advanced gastrointestinal cancer treated with chemotherapy.
Xu H; Mao Y; Dai Y; Wang Q; Zhang X
Onkologie; 2009 May; 32(5):246-52. PubMed ID: 19420970
[TBL] [Abstract][Full Text] [Related]
35. Trastuzumab administration associated with change in HER2 status.
Dawood S; Resetkova E; Gonzalez-Angulo AM
Clin Breast Cancer; 2008 Aug; 8(4):366-9. PubMed ID: 18757266
[TBL] [Abstract][Full Text] [Related]
36. Targeted therapy for cancer: the HER-2/neu and Herceptin story.
Ross JS; Gray GS
Clin Leadersh Manag Rev; 2003; 17(6):333-40. PubMed ID: 14692077
[TBL] [Abstract][Full Text] [Related]
37. [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].
Dank M
Orv Hetil; 2001 Nov; 142(46):2563-8. PubMed ID: 11770175
[TBL] [Abstract][Full Text] [Related]
38. HER-2/neu determination in blood plasma of patients with HER-2/neu overexpressing metastasized breast cancer: a longitudinal study.
Hoopmann M; Neumann R; Tanasale T; Schöndorf T
Anticancer Res; 2003; 23(2A):1031-4. PubMed ID: 12820343
[TBL] [Abstract][Full Text] [Related]
39. HER-2-targeted therapy: lessons learned and future directions.
Nahta R; Esteva FJ
Clin Cancer Res; 2003 Nov; 9(14):5078-84. PubMed ID: 14613984
[TBL] [Abstract][Full Text] [Related]
40. Frequency of circulating Tregs with demethylated FOXP3 intron 1 in melanoma patients receiving tumor vaccines and potentially Treg-depleting agents.
de Vries IJ; Castelli C; Huygens C; Jacobs JF; Stockis J; Schuler-Thurner B; Adema GJ; Punt CJ; Rivoltini L; Schuler G; Coulie PG; Lucas S
Clin Cancer Res; 2011 Feb; 17(4):841-8. PubMed ID: 21177412
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
